4:53 PM
 | 
Jul 10, 2019
 |  BC Extra  |  Politics & Policy

CMS’s new CKD payment models could be mixed bag for drug companies

A set of five different payment models announced by the Centers for Medicare & Medicaid Services for patients with chronic kidney disease or end-stage renal disease could be a boon for companies that have taken a renewed interest in new treatments for renal disease. However, those with supportive care agents for patients on dialysis could take a hit.

The goal of the payment models announced Wednesday is to decrease the use of dialysis facilities for patients with CKD or ESRD by providing incentive payments to physicians who transition patients to in-home care or kidney transplant....

Read the full 458 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >